Daiichi Sankyo Appoints New Corporate Officers

February 21, 2020

Corporate

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
https://www.daiichisankyo.com

TOKYO, Japan (February 21, 2020) – Daiichi Sankyo Company, Limited today announced the appointment of new corporate officers, CIO and CISO effective from April 1, 2020.

1. Changes to Corporate Officers

Name	Current Responsibilities	New Responsibilities
Toshiaki Tojo	Member of the Board Senior Executive Officer In charge of Vaccine Business and Quality & Safety Management	Member of the Board
Masahiko Ohtsuki	Executive Officer Vice President of Business Development & Licensing Dept.	Senior Executive Officer Head of Digital Transformation Management Div.
Shoji Hirashima	Executive Officer Head of Global Brand Strategy Div.	Senior Executive Officer Head of Global Brand Strategy Div.
Hironobu Furuta	Corporate Officer Head of Corporate Affairs Div.	Executive Officer Head of Corporate Affairs Div.
Masayuki Yabuta	Corporate Officer Head of Biologics Div.	Executive Officer Head of Biologics Div.
Wataru Takasaki	Corporate Officer Head of R&D Div. and Vice President of Oncology Function	Executive Officer Head of R&D Div.
Shinichi Tobita	Corporate Officer Vice President of Tokyo Branch, Sales & Marketing Div.	Corporate Officer Vice President of Marketing Management Dept., Sales & Marketing Div.
Hideyuki Hirano	Corporate Officer Vice President of External Affairs Dept.	Corporate Officer In charge of External Affairs
Yoshikazu Fukuchi	Corporate Officer Head of Medical Affairs Div.	Corporate Officer In charge of Medical Affairs
Seiichiro Kumakura	Corporate Officer Vice President of Research Function, R&D Div.	Corporate Officer Vice President of Translational Medicine Function, R&D Div.
Hironobu Saito	Corporate Officer Vice President of Oncology Clinical Development Dept., Oncology Function, R&D Div.	Corporate Officer Head of Medical Affairs Div.
Miyuki Arai	Head of Quality & Safety Management Div.	Head of Quality Assurance & Regulatory Affairs Div.
Toru Takahashi	Vice President of Modality Research Laboratories, Biologics Div.	Corporate Officer Vice President of Research Function, R&D Div.
Hiroto Kashiwase	Head of Pharmaceutical Technology Div.	Corporate Officer Head of Pharmaceutical Technology Div.
Naoto Tsukaguchi	Vice President of Legal Affairs Dept., Corporate Affairs Div.	Corporate Officer Vice President of Legal Affairs Dept., Corporate Affairs Div.
Akio Sakurai	Vice President of Sales Planning Dept., Sales & Marketing Div.	Corporate Officer Vice President of Sales Planning Dept., Sales & Marketing Div.
Toshinori Agatsuma	Vice President of Oncology Research Laboratories I, Oncology Function, R&D Div.	Corporate Officer Vice President of Oncology Research Laboratories I, Research Function, R&D Div.

◇Ryoji Nagasaka (current Executive Officer) will be appointed full-time Corporate Advisor as of April 1st, 2020.

2. Appointment of CIO and CISO

Chief Information Officer (CIO)	Masahiko Ohtsuki
Chief Information Security Officer (CISO)	Hironobu Furuta

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.

Back to index